The Clinical Pharmacokinetics of Lu AA21004 and its Major Metabolite in Healthy Young Volunteers

Basic and Clinical Pharmacology and Toxicology

Volumn 111, Issue 3, 2012, Pages 198-205

  Areberg, Johan ^a   Søgaard, Birgitte ^a   Højer, Astrid Maria ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DRUG METABOLITE; LU AA34443; PLACEBO; UNCLASSIFIED DRUG; VORTIOXETINE;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; FEMALE; HUMAN; KIDNEY CLEARANCE; MALE; PHARMACOKINETICS; PRIORITY JOURNAL; STANDARD; URINALYSIS; VALIDATION STUDY; VOLUNTEER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; SULFIDES; YOUNG ADULT;

EID: 84865109944     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2012.00886.x     Document Type: Article

References (17)

1. Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG et al. Discovery of 1-[2-(2, 4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 2011;54:3206-21.
2. Mørk A, Pehrson A, Brennum LT, Møller Nielsen S, Zhong H, Lassen AB et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 2012;340:666-75.
3. Areberg J, Luntang-Jensen M, Søgaard B, Nilausen DØ. Occupancy of the Serotonin Transporter after Administration of Lu AA21004 and its Relation to Plasma Concentration in Healthy Subjects. Basic Clin Pharmacol Toxicol 2012;110:401-4.
4. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 2011;18:1-12.
5. Nilausen D, Højer A-M, Bendahl L. Absorption, metabolism, and excretion of an oral dose of [14C]-Lu AA21004 50 mg in healthy men. J Clin Pharmacol 2009;49:1113.
6. Wang Y, Wojtkowski T, Ross G, Smith S, Nomikos G. Effect of multiple doses of rifampicin on the single dose pharmacokinetics of Lu AA21004. J Clin Pharmacol 2010;50:1082.
7. Buchbjerg JK, Højer A-M, Jensen KG, Søgaard B. Assessment of the CYP2C19 interaction potential of Lu AA21004. J Clin Pharmacol 2009;49:1119.
8. Wang Y, Zhang W, Agyeman A, Ross G, Astruc B, Nomikos G. Lack of effect of multiple doses of Lu AA21004 on the pharmacodynamics and pharmacokinetics of aspirin. J Clin Pharmacol 2010;50:1082.
9. Wang Y, Wojtkowski T, Hanson E, Harris S, Karim A. An open-label, multiple-dose study in healthy adults to assess the drug interaction potential of Lu AA21004 using the Indiana cocktail. J Clin Pharmacol 2009;49:1114.
10. Wang Y, Wojtkowski T, Devoti A, Priestley A, Karim A. Effect of Lu AA21004 on the pharmacokinetics and pharmacodynamics of ethinyl estradiol (30 μg) and levonorgestrel (150 μg) in healthy adult women. J Clin Pharmacol 2009;49:1114.
11. Wang Y, Munsaka M, Hanson E, Serenko M, Medlock M, Nomikos G. The effect of multiple-doses of fluconazole, or ketoconazole, on the single-dose pharmacokinetic profile of Lu AA21004 in healthy adult subjects. AAPS J 2010;12(S2).
12. Wang Y, Wojtkowski T, Agyemang A, Karim A. Effect of food on the pharmacokinetics of Lu AA21004 in healthy volunteers. J Clin Pharmacol 2009;49:1115.
13. Wang Y, Wojtkowski T, Agyemang A, Homery MC, Karim A. Relative bioavailability of two formulation of Lu AA21004. J Clin Pharmacol 2009;49:1114.
14. Chen G, Wang Y, Lee RD, Zhao Z, Nomikos GG. Effects of multiple doses of Lu AA21004 on the single-dose pharmacokinetics and pharmacodynamics of diazepam. J Clin Pharmacol 2011;51:1350.
15. Chen G, Wang Y, Nudurupati S, Nomikos GG, Serenko M. Effect of multiple doses of bupropion on the steady-state pharmacokinetics of Lu AA21004 in healthy adults. J Clin Pharmacol 2011;51:1350.
16. World Medical Association (WMA). Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. WMA, Ferney-Voltaire, France, 2000.
17. ICH. ICH Harmonised Tripartite Guideline E6, Step 5: Guideline for Good Clinical Practice. Adopted by CPMP July 1996 (CPMP/ICH/135/95 & CPMP/768/97) and by FDA May 1997 (Guidance for Industry, ICH E6).